Literature DB >> 12195383

Innate and acquired resistance to amebiasis in bangladeshi children.

Rashidul Haque1, Priya Duggal, Ibnekarim M Ali, Mohammad Bakthiar Hossain, Dinesh Mondal, R Bradley Sack, Barry M Farr, Terri H Beaty, William A Petri.   

Abstract

Entamoeba histolytica infection and colitis occurred in 55% and 4%, respectively, of a cohort of Bangladeshi preschool children observed for 2 years. DNA typing demonstrated that infecting E. histolytica isolates were genetically diverse. Innate resistance to infection in children was linked to the absence of serum anti-trophozoite IgG. Most children who lacked serum anti-trophozoite IgG failed to develop it in response to a new infection. The serum anti-trophozoite IgG response clustered in families, which is consistent with genetic inheritance. Acquired resistance to infection was linked to intestinal IgA against the carbohydrate-recognition domain of the E. histolytica galactose N-acetyl-d-galactosamine lectin. This was associated with an 86% reduction in new infection over 1 year. Amebiasis is a common and potentially serious infection in children from Dhaka, and both innate and acquired immune responses limit infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12195383     DOI: 10.1086/341566

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  44 in total

Review 1.  Cardiac involvement with parasitic infections.

Authors:  Alicia Hidron; Nicholas Vogenthaler; José I Santos-Preciado; Alfonso J Rodriguez-Morales; Carlos Franco-Paredes; Anis Rassi
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

2.  Mucosal immunity to asymptomatic Entamoeba histolytica and Entamoeba dispar infection is associated with a peak intestinal anti-lectin immunoglobulin A antibody response.

Authors:  Mohamed D Abd-Alla; Terry F G H Jackson; Tyson Rogers; Selvan Reddy; Jonathan I Ravdin
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 3.  Crosstalk at the initial encounter: interplay between host defense and ameba survival strategies.

Authors:  Xiaoti Guo; Eric Houpt; William A Petri
Journal:  Curr Opin Immunol       Date:  2007-08-16       Impact factor: 7.486

4.  CpG-oligodeoxynucleotide is a potent adjuvant with an Entamoeba histolytica Gal-inhibitable lectin vaccine against amoebic liver abscess in gerbils.

Authors:  Catherine P A Ivory; Kathy Keller; Kris Chadee
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

5.  Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon.

Authors:  Xiaoti Guo; Lisa Barroso; Steven M Becker; David M Lyerly; Thomas S Vedvick; Steven G Reed; William A Petri; Eric R Houpt
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

6.  Comparative genomic hybridizations of Entamoeba strains reveal unique genetic fingerprints that correlate with virulence.

Authors:  Preetam H Shah; Ryan C MacFarlane; Dhruva Bhattacharya; John C Matese; Janos Demeter; Suzanne E Stroup; Upinder Singh
Journal:  Eukaryot Cell       Date:  2005-03

7.  Members of the Entamoeba histolytica transmembrane kinase family play non-redundant roles in growth and phagocytosis.

Authors:  Sarah N Buss; Shinjiro Hamano; Alda Vidrich; Clive Evans; Yan Zhang; Oswald R Crasta; Bruno W Sobral; Carol A Gilchrist; William A Petri
Journal:  Int J Parasitol       Date:  2010-01-18       Impact factor: 3.981

8.  The NF-kappaB p50 subunit is protective during intestinal Entamoeba histolytica infection of 129 and C57BL/6 mice.

Authors:  Kyou-Nam Cho; Stephen M Becker; Eric R Houpt
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

Review 9.  Laboratory diagnosis of amebiasis.

Authors:  Mehmet Tanyuksel; William A Petri
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

Review 10.  Amebic infection in humans.

Authors:  Gourdas Choudhuri; Murali Rangan
Journal:  Indian J Gastroenterol       Date:  2012-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.